Respiratory syncytial virus (RSV): clinical risks, diagnosis and prevention

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in infants and a significant factor in hospitalizations among the elderly. Although the infection often presents as a mild acute respiratory infection, its systemic impact, seasonal dynamics, and burden on the health care system make RSV the subject of close clinical and epidemiological attention.

According to estimates World Health Organization, RSV causes millions of infections in children under 5 years of age each year, and severe forms can lead to hospitalization and increased mortality in vulnerable groups.

Virological characteristics and mechanisms of pathogenesis

RSV is a single-stranded RNA virus of the Pneumoviridae family. A key feature is the ability to form syncytia, multinucleated cellular structures resulting from the fusion of infected cells of the respiratory tract epithelium. It is this property that explains the deep involvement of the bronchioles.

The main pathophysiological processes in RSV infection:

• swelling of the bronchial mucosa

• mucus hypersecretion

• impaired mucociliary clearance

• partial or complete obstruction of the small airways

In infants, the anatomical narrowness of the bronchioles increases the risk of respiratory failure even with moderate inflammation.

Epidemiology: seasonality and circulation changes

RSV has a clear seasonal pattern, peaking in the colder months. Following global lockdowns during the COVID-19 pandemic, many countries have seen seasonal shifts and increased incidence among older children who had not previously been exposed to the virus.

Analytical observations indicate:

• cyclicality of increases in incidence

• variations in the intensity of flashes

• the impact of social mobility on the spread of the virus

Clinical spectrum: from rhinitis to bronchiolitis

Clinical manifestations of RSV vary depending on age and immune status.

In healthy adults, the course is usually limited to upper respiratory tract symptoms:

• cold

• moderate cough

• subfebrile temperature

In infants and people with risk factors, the following are possible:

• tachypnea

• wheezing

• intercostal space retraction

• hypoxia

Specialists Mayo Clinic emphasize that RSV is the leading cause of bronchiolitis in children in the first year of life.

Comparative analysis of RSV and other respiratory viruses

This comparison demonstrates the specific role of RSV in pediatric practice.

Severity criteria and «red flags» for RSV

Although RSV often begins as a simple respiratory infection, some patients can develop a rapid deterioration in their condition. It is important to recognize the signs that indicate the risk of respiratory failure.

Clinically significant markers of severity include:

• respiratory rate exceeding the age norm

• retraction of the intercostal spaces or jugular fossa

• expansion of the nasal wings during breathing

• oxygen saturation below 94%

• infant refusal to eat

• severe lethargy or drowsiness

In infants, even a brief drop in oxygen levels may require hospitalization. In elderly patients, a sudden deterioration in general condition or decompensation of chronic diseases is a danger signal.

This approach allows us to clearly distinguish between «mild cases» and situations that require emergency medical care.

High-risk groups and clinical consequences

The highest risk of severe disease is:

• premature babies

• infants up to 6 months

• patients with congenital heart defects

• people with chronic lung diseases

• people over 65 years old

In these groups, infection can cause:

• severe bronchiolitis

• pneumonia

• need for oxygen support

• hospitalization in the intensive care unit

RSV Diagnosis: Laboratory Strategy

Clinical diagnosis may be obvious during the seasonal upswing, but laboratory confirmation is necessary in:

• hospitalization

• severe course

• immunodeficiency states

• the need to differentiate with influenza or COVID-19

Diagnostic methods:

• PCR of nasopharyngeal swab

• rapid antigen tests

• determination of inflammation markers

• oxygen saturation assessment

PCR method remains the "gold standard" due to its high sensitivity.

According to the position FDA, new diagnostic platforms must meet criteria of analytical accuracy and clinical validity.

Interpreting RSV test results

Laboratory confirmation of infection not only establishes the diagnosis, but also helps determine surveillance tactics.

It is important to understand that a positive PCR result does not always correlate with the severity of symptoms. The clinical assessment of the patient remains decisive.

Therapeutic approaches

Most cases of RSV are treated symptomatically. Key principles:

• hydration support

• temperature control

• respiratory function monitoring

• oxygen support for hypoxia

Specific antiviral agents are of limited use. In recent years, prophylactic monoclonal antibodies have been actively developed for children at risk.

Prevention and strategic control

RSV prevention includes:

• limiting contact between infants during peak season

• hand hygiene

• isolation of patients

• use of preventive immune drugs in risk groups

Many countries are implementing new vaccination strategies for pregnant women and the elderly, which may reduce the overall burden of disease.

Research prospects

Analytical research focuses on:

• development of a universal vaccine

• long-term effects of RSV in childhood

• the influence of the virus on the formation of bronchial asthma

• improving rapid diagnostic platforms

Post-infectious sequelae and long-term effects of RSV

In most cases, recovery occurs without consequences, however, some children after bronchiolitis retain increased bronchial reactivity.

Possible long-term effects:

• prolonged dry cough

• repeated episodes of wheezing

• predisposition to obstructive bronchitis

• increased susceptibility to respiratory infections

Researchers continue to study the link between severe RSV in early childhood and the risk of developing asthma. So far, this link is considered to be an associative rather than a direct causal mechanism.

FAQ: Key questions about respiratory syncytial virus (RSV)

Can an adult get re-infected with RSV?
Yes. Immunity after infection is not lifelong. Re-infections are possible throughout life, but in healthy adults the course is usually milder.

Does RSV always lead to bronchiolitis?
No. Bronchiolitis is a complication that is more common in infants due to the anatomy of the airway. In older children and adults, the infection is often limited to upper respiratory symptoms.

How is RSV different from the common cold?
Clinically, it is difficult to distinguish, especially in the early stages. However, RSV is more likely to cause wheezing, bronchial obstruction, and severe respiratory distress in young children. PCR diagnostics are used for accurate confirmation.

Is there a vaccine against RSV?
New vaccination and immunoprophylactic strategies are already being implemented in various countries, particularly for pregnant women and the elderly, to reduce the risk of severe disease in newborns and elderly patients.

When do you need to see a doctor urgently?
Immediate medical attention is needed if:

• difficult or rapid breathing

• cyanosis of the lips

• severe drowsiness

• infant refusal to eat

• decreased oxygen saturation levels

Is RSV linked to later development of asthma?
Some studies suggest that severe bronchiolitis in early childhood may be associated with an increased risk of bronchial hyperresponsiveness later in life, but the mechanism of this association remains to be studied.

Are antibiotics needed for RSV?
No, unless there is a confirmed bacterial infection. RSV is a virus and antibiotics do not affect its course.

Respiratory syncytial virus (RSV) remains a major cause of lower respiratory tract infections in young children and a significant risk for older adults. Although RSV infection often begins as a common upper respiratory tract infection, its clinical course can change rapidly, especially in infants, premature infants, and patients with comorbidities. Therefore, early recognition of RSV symptoms, assessment of severity criteria, and, if necessary, laboratory diagnosis of RSV are essential.